【摘要】 目的:观察每周多西紫杉醇方案治疗晚期非小细胞肺癌和乳腺癌临床疗效及副作用。方法:36例晚期非小细胞肺癌和乳腺癌患者,周剂量多西紫杉醇化疗方案为25~40 mg/m2,第1、8、15天给药,多西紫杉醇联合顺铂治疗晚期非小细胞肺癌,联合顺铂或卡培他滨等治疗乳腺癌。28天为1个周期。结果:36例患者按WHO标准评价疗效及毒性,CR 3例,PR 10例,SD9例,PD 14例,总有效率为36.1%。主要副作用为轻度血液学毒性反应,白细胞下降发生率25.0%,Ⅲ度白细胞下降发生率6.0%,Ⅰ~Ⅱ度贫血发生率5.0%,Ⅱ~Ⅲ度血小板下降发生率3.0%,非血液学毒性低。结论:周剂量多西紫杉醇化疗方案治疗晚期非小细胞肺癌和乳腺癌疗效好,毒性低,患者能耐受。更多还原

【Abstract】 Objective:To evaluate the therapeutic effect and side effect of weekly docetaxel in patients with advanced non-small-cell lung cancer and breast cancer.Methods:Thirty-six patients with advanced non-small-cell lung cancer and breast cancer received weekly docetaxel(25-40 mg/m~2 on Day1,8,15 every 4 weeks) in combination with cisplatin or with cisplatin or capecitabine or epirubicin.Results:All the therapeutic effects and toxicities were evaluated by WHO standard.Complete response was observed in 3 cases,partial response in 10 cases,stable disease in 9 cases and progressive disease in 12 cases,with a total response rate of 36.1%.The main toxicity reaction was mild hematological toxicities.The incidence of leukopenia was 25.0% and that of grade III leucopenia 6.0%.The incidence rate of grade 1 to 2 anemia was 5.0%.Other non-hematological toxicities were rarely seen.Conclusions:Weekly docetaxel is safe and effect for treatment of patients with advanced breast cancer or non-small-cell lung cancer.更多还原